spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  sDNA 

 HSMN NewsFeed - 21 May 2021
Modeling Data Showed Cologuard(R) Was Superior to Fecal Immunochemical Test (FIT) on Cost Effectiveness and Colorectal Cancer Incidence and Mortality
Diagnostics Oncology
 HSMN NewsFeed - 17 May 2019
Exact Sciences Presents New Data Reinforcing Performance of Cologuard(R)
Diagnostics Gastroenterology Oncology
 HSMN NewsFeed - 23 Mar 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2013
Chimerix Appoints Linda M. Richardson as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Chimerix Appoints Michael D. Rogers, Ph.D., as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2013
Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 May 2011
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Apr 2010
Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 8 Aug 2008
EXACT Sciences Announces Next Generation Stool-based DNA Technology Study Results of 92% for Colorectal Cancer Detection
Diagnostics Gastroenterology Oncology
 HSMN NewsFeed - 6 Mar 2008
Colorectal Cancer Screening Guidelines Released by the American Cancer Society Include EXACT Sciences' Stool DNA Technology
Diagnostics Oncology
 HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2007
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2007
CytoGenix Announces Hiring of New Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jul 2007
EXACT Sciences' DNA Technology is Preferred Non-Invasive Method for Colorectal Cancer Screening Among Patients
Diagnostics Oncology
 HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2007
La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated in Three Studies at International Lupus Congress
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2007
La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2006
La Jolla Pharmaceutical Provides Update on MAA Application in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
sDNA
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.